Albert David appoints Amit Mahla as Additional Director and Whole-time Director & CEO for 5 years

Ceo Appointed ExternalManagement Changes View source PDF Explain this filing

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹710.50

prior close

₹725.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-0.2% vs market

Pharmaceuticals peers, median of 162sector+0.5%+0.1% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-0.7

15m

-0.7

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+0.8-0.2+0.5+0.1

Next day

+0.5+0.1+0.4+1.5-0.9

+0.2+0.0+0.2+1.1-0.9

-0.7-0.6-0.2+0.8-1.6

-0.4-0.9+0.5+1.0-1.3

-1.8+0.2-1.9+2.7-4.5

+0.9+1.2-0.3+2.3-1.4

15d

-2.2+0.7-2.9+4.3-6.5

-3.3-0.4-2.9+2.6-5.9

+25.5+5.2+20.4+2.8+22.7

+19.6+5.4+14.2+7.1+12.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Albert David's Board has appointed Mr. Amit Mahla as Additional Director and Whole-time Director and CEO for 5 years (June 19, 2026 to June 18, 2031). He was already serving as CEO since May 12, 2026. Remuneration is fixed till March 31, 2027. Both appointments need shareholder approval at the 87th AGM. Mr. Mahla, 52, has 28 plus years in pharma with companies like Cipla, Glenmark, Sun Pharma, and JB Pharma.

Likely market impact

Formalizes leadership for 5 years with experienced pharma hand from JB Pharma. Brings continuity but pending shareholder nod at the 87th AGM.